Cargando…

ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors

Recurrence and progression to higher grade lesions are key biological events and characteristic behaviors in the evolution process of glioma. Malignant astrocytic tumors such as glioblastoma (GBM) are the most lethal intracranial tumors. However, the clinical practicability and significance of molec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Jinquan, Zhang, Chuanbao, Zhang, Wei, Wang, Guangzhi, Yao, Kun, Wang, Zhiliang, Li, Guanzhang, Qian, Zenghui, Li, Yongli, Jiang, Tao, Jiang, Chuanlu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5043074/ https://www.ncbi.nlm.nih.gov/pubmed/27713914 http://dx.doi.org/10.18632/oncoscience.317

Ejemplares similares

Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas
por: Cai, Jinquan, et al.
Publicado: (2016)

ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples
por: Cai, Jinquan, et al.
Publicado: (2014)

Immunohistochemical Expression of IDH1, ATRX, Ki67, GFAP, and Prognosis in Indonesian Glioma Patients
por: Priambada, Dody, et al.
Publicado: (2023)

Loss of ATRX, associated with DNA methylation pattern of chromosome end, impacted biological behaviors of astrocytic tumors
por: Cai, Jinquan, et al.
Publicado: (2015)

Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1(R132H) mutation and may predict better prognosis among glioblastomas without the IDH1 mutation and ATRX loss
por: Cai, Hong-Qing, et al.
Publicado: (2018)

IMMUNOHISTOCHEMICAL ANALYSIS BY KI67 AND IDH1 IN PATIENTS WITH CHONDROSARCOMA
por: RIBEIRO, MARCELO BARBOSA, et al.
Publicado: (2023)

Identification of IDH-mutant gliomas by a prognostic signature according to gene expression profiling
por: Wang, Qiangwei, et al.
Publicado: (2018)

Low correlation between Ki67 assessed by qRT-PCR in Oncotype Dx score and Ki67 assessed by Immunohistochemistry
por: Selmani, Zohair, et al.
Publicado: (2022)

Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer
por: Besusparis, Justinas, et al.
Publicado: (2016)

Ki‐67 assessment—agreeability between immunohistochemistry and flow cytometry in canine lymphoma
por: Rigillo, Antonella, et al.
Publicado: (2021)

IDH1, ATRX, and BRAFV600E mutation in astrocytic tumors and their significance in patient outcome in north Indian population
por: Chatterjee, Debajyoti, et al.
Publicado: (2018)

IDH1 R132H Mutation Is Accompanied with Malignant Progression of Paired Primary-Recurrent Astrocytic Tumours
por: Mu, Luyan, et al.
Publicado: (2017)

ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma
por: Han, Bo, et al.
Publicado: (2020)

Assessment of p16 and Ki67 Immunohistochemistry Expression in Squamous Intraepithelial Lesion with Cytohistomorphological Correlation
por: Ghosh, Apurv, et al.
Publicado: (2020)

Prognostic value of the immunohistochemistry correlation of Ki-67 and p53 in squamous cell carcinomas of the larynx
por: Rodrigues, Ricardo Boose, et al.
Publicado: (2015)

ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma
por: Babikir, Husam, et al.
Publicado: (2021)

Arterial Spin Labeling Perfusion in Determining the IDH1 Status and Ki-67 Index in Brain Gliomas
por: Batalov, Artem I., et al.
Publicado: (2022)

MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status
por: Li, Guanzhang, et al.
Publicado: (2018)

Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss
por: Li, Xia, et al.
Publicado: (2017)

Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma
por: Lin, Lin, et al.
Publicado: (2021)

Characterization of an IDH1 R132H Rabbit Monoclonal Antibody, MRQ-67, and Its Applications in the Identification of Diffuse Gliomas
por: Copaciu, Raul, et al.
Publicado: (2023)

Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia
por: Kushitani, Kei, et al.
Publicado: (2018)

Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer
por: Sinn, Hans-Peter, et al.
Publicado: (2017)

Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival
por: Chaurasia, Ajay, et al.
Publicado: (2016)

ATRX immunostaining predicts IDH and H3F3A status in gliomas
por: Ebrahimi, Azadeh, et al.
Publicado: (2016)

IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma
por: Zeng, Ailiang, et al.
Publicado: (2015)

Ki-67 gene expression
por: Uxa, Sigrid, et al.
Publicado: (2021)

A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma
por: Uguen, Arnaud, et al.
Publicado: (2015)

Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer
por: Serna, Garazi, et al.
Publicado: (2020)

To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis
por: Di Rosa, Francesca, et al.
Publicado: (2021)

Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
por: Tesileanu, C. Mircea S., et al.
Publicado: (2021)

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
por: Jiao, Yuchen, et al.
Publicado: (2012)

Corrigendum: To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis
por: Di Rosa, Francesca, et al.
Publicado: (2021)

The prognostic IDH1(R132) mutation is associated with reduced NADP(+)-dependent IDH activity in glioblastoma
por: Bleeker, Fonnet E., et al.
Publicado: (2010)

Adult IDH Wild-Type Glioblastoma Ultrastructural Investigation Suggests a Possible Correlation between Morphological Biomarkers and Ki-67 Index
por: Familiari, Pietro, et al.
Publicado: (2023)

The intrinsically disorderly story of Ki-67
por: Remnant, Lucy, et al.
Publicado: (2021)

Rab27a Was Identified as a Prognostic Biomaker by mRNA Profiling, Correlated with Malignant Progression and Subtype Preference in Gliomas
por: Wang, Hongjun, et al.
Publicado: (2014)

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas
por: Leeper, Heather E., et al.
Publicado: (2015)

Prognostic Value of Ki67 in Patients with Stage 1–2 Endometrial Cancer: Validation of the Cut-off Value of Ki67 as a Predictive Factor
por: Jiang, Peng, et al.
Publicado: (2020)

How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and Gynecopathologists
por: Varga, Zsuzsanna, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_8qubu8evi0860lbta41i78j8a9